ECS Botanics generated revenue of A$5 million in the first quarter of FY25, up 22% on last year and 11% on the prior quarter, as exports and sales of in-house products began to take off.
The company said its B2C business, launched in May, is “growing strongly”, underpinned by a strategy to market products directly to prescribing doctors.
“Introducing a B2C strategy has provided a valuable diversification in the business, particularly as B2B sales continue to come under pressure due to large volumes of product in the market,” the firm said.
Continue reading...
